COBAS AMPLICOR CT/NG TEST FOR CHLAMYDIA TRACHOMATIS

{0}------------------------------------------------ AUG 1 0 2006 K053287 ## 510(k) Summary -- COBAS AMPLICOR CT/NG test for Chlamydia trachomatis with Roche Scripts Accessory Introduction נייר בין ליי According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence Submitter name, address, contact Roche Diagnostics 9115 Hague Rd Indianapolis IN 46250 (317) 521-3723 Contact person: Theresa M. Ambrose Date prepared: November 23, 2005 Device Name Proprietary Name: COBAS AMPLICOR CT/NG test for Chlamydia trachomatis; Roche Scripts for COBAS AMPLICOR CT/NG Test (Roche Scripts Accessory) Common name: Chlamydia trachomatis test system; software accessory Classification name: DNA probe, nucleic acid amplification, chlamydia Device Description The COBAS AMPLICOR CT/NG test for Chlamydia trachomatis is a qualitative in vitro test for the detection of C. trachomatis DNA in urine from symptomatic or asymptomatic males, in endocervical swab specimens from symptomatic or asymptomatic females, and in urethral swab specimens from symptomatic males as evidence infection with C. trachomatis. C. trachomatis DNA is detected by Polymerase Chain Reaction (PCR) amplification of target DNA and by hybridization capture of amplified target using the AMPLICOR analvzer. The Roche Scripts for COBAS AMPLICOR CT/NG Test accessory consists of a compact disc (CDs) containing scripts to direct the automated Tecan Genesis RSP 150 workstation to process swab samples or control material for analysis. Continued on next page .. : {1}------------------------------------------------ # 510(k) Summary, Continued | Intended use | The COBAS AMPLICOR CT/NG test for Chlamydia trachomatis is a qualitative in vitro test for the detection of C. trachomatis plasmid DNA in urine from males and females, in endocervical swab specimens, and in male urethral swab specimens as evidence of symptomatic or asymptomatic infection with C. trachomatis. C. trachomatis DNA is detected by Polymerase Chain Reaction (PCR) amplification of target DNA and by hybridization capture of amplified target using the COBAS AMPLICOR analyzer. | |---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | The Roche Scripts for COBAS AMPLICOR CT/NG Test are intended to provide software scripts to direct the automated Tecan Genesis RSP 150 Workstation to process swab samples or control material for analysis using either of the following 510(k)-cleared assay test systems: <ul><li>COBAS AMPLICOR™ CT/NG test for Chlamydia trachomatis</li><li>COBAS AMPLICOR™ CT/NG test for Neisseria gonorrhoeae</li></ul> | | Predicate Device | We claim equivalence to the currently marketed COBAS AMPLICOR CT/NG test for Chlamydia trachomatis cleared under K973718. | | Comparison - similarities | The table below shows the similarities between the COBAS AMPLICOR CT/NG test for Chlamydia trachomatis with optional Roche Scripts accessory and the predicate device: | Continued on next page: : {2}------------------------------------------------ #### DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three overlapping wings, representing the department's mission to protect the health of all Americans and provide essential human services. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle. Public Health Service Food and Drug Administration 2098 Gaither Road Rockville MD 20850 Theresa Ambrose Bush, Ph.D., RAC Regulatory Affairs Principal Centralized Diagnostics Roche Diagnostics, Inc. 9115 Hague Road Indianapolis, IN 46250-0416 AUG 1 0 2006 Re: k053287 Trade/Device Name: Roche Scripts for COBAS AMPLICOR CT/NG Test Regulation Number: 21 CFR8866.3120 Regulation Name: Chlamydia serological reagents Regulatory Class: Class II Product Code: MKZ Dated: June 30, 2006 Received: July 3, 2006 Dear Dr. Bush: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). {3}------------------------------------------------ Page 2 - This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0484. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html Sincerely yours, Sale, a Hogg Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ ## Indications for Use 510(k) Number (if known): K053287 Device Name: Roche Scripts for COBAS AMPLICOR CT/NG Test Indications For Use: The Roche Scripts for COBAS AMPLICOR CT/NG Test are intended to provide The Room Lorect the automated Tecan Genesis RSP 150 Workstation to process swab samples or control material for analysis using either of the following 510(k)cleared assay test systems: - COBAS AMPLICOR™ CT/NG test for Chlamydia trachomatis . - COBAS AMPLICOR™ CT/NG test for Neisseria gonorrhoeae . Prescription Use XXXX (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 807 Subpart C) ### (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Fuderic tu. Locke Division Sign-Off Page 1 of | | | | Office of In Vitro Diagnostic Device Evaluation and Safety Confidential